During ubiquitination, a group of enzymes called E3 ubiquitin ligases attach a small protein called ubiquitin to other proteins. This tagging, in turn, helps determine the fate of the targeted ...

This review highlights the critical role of ubiquitination in governing the functionality of cancer stem cells (CSCs), ...

Trimtech Therapeutics has closed a seed funding round of $31m (£25m) to advance its pipeline of CNS penetrant therapeutics.

DelveInsight's Molecular Glues Market Insights report includes a comprehensive understanding of current treatment practices, ...

E3-ubiquitin ligase inducible degrader of the LDL receptor has a similar function to PCSK9 and is a potential therapeutic target. A desirable treatment target for HoFH patients is LDL-C ≤1.8 mmol/l.

Parkin, an E3 ubiquitin ligase, is recruited to the outer mitochondrial membrane through PINK1 phosphorylation, promoting mitochondrial degradation processes. OMA1 is a mitochondrial inner ...

TRIMTECH Therapeutics raises $31M to enhance its TRIMTAC platform, targeting protein aggregates in neurodegenerative diseases for improved therapeutic outcomes.

Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...

This review highlights the critical role of ubiquitination in governing the functionality of cancer stem cells (CSCs), ...